MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2017 International Congress

    An Unusual Cause of Rhabdomyolysis in Parkinson’s disease

    Y. Pitakpatapee, C. Satukijchai, P. Srivanitchapoom (Bangkok, Thailand)

    Objective: To describe an unusual cause of rhabdomyolysis in patient with advanced Parkinson’s disease (PD) treated with levodopa. Background: Rhabdomyolysis is a serious and life-threatening…
  • 2017 International Congress

    Fibroblasts Implanted in Internal Pallidum of Parkinsonian Macaques Exert L-Dopa-Sparing Activity

    E. Bezard, J. Finberg, W.K. Ko, Q. Li, B. Dehay, E. Pioli, Y. Yair (Bordeaux, France)

    Objective: To assess the effects of autologous implantation of fibroblasts in the internal globus pallidus of dyskinetic MPTP-lesioned monkeys upon motor behaviour and L-DOPA response.…
  • 2017 International Congress

    Effect of levodopa-carbidopa intestinal gel on dyskinesia: Design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients

    A. Antonini, W. Poewe, D. Standaert, C. Zadikoff, S. Dubow, L. Bergmann, A. Yegin, C. Hall, W. Robieson, V. Felipe, L. Barbato (Venice, Italy)

    Objective: To examine the effect of levodopa-carbidopa intestinal gel (LCIG, designated carbidopa-levodopa enteral suspension in the US) treatment relative to that of optimized medical treatment…
  • 2016 International Congress

    Twelve-week sensor assessment in Parkinson’s disease: Impact on quality of life

    J.M.T. Van Uem, K.S. Maier, A.T. Santos, O. Fagerbakke, F. Larsen, J.J. Ferreira, W. Maetzler (Tübingen, Germany)

    Objective: To evaluate the effects of using wearables over a long time period on Health-Related Quality of Life (HRQoL) in Parkinson's disease (PD) patients. Background:…
  • 2016 International Congress

    Synaptic homeostasis in Parkinson’s disease: An high-density EEG study in different stage of the disease

    S. Galati, S. Sarasso, C. Moeller, A. Kalein-Lang, C. Staedler (Lugano, Switzerland)

    Objective: In order to corroborate these findings, we submitted 29 Parkinson's disease (PD) patients with different stage of disease to an all-night high-density EEG (hd-EEG)…
  • 2016 International Congress

    Dyskinesias-reduced-self-awareness and theory of mind in Parkinson’s disease: A novel frame of interpretation

    S. Palermo, M. Amanzio, M. Zibetti, L. Lopiano (Turin, Italy)

    Objective: To analyze the existence of a relationship between Dyskinesias-reduced-self-awareness (DRSA) and abilities related to cognitive and affective Theory of Mind (ToM), which may represent…
  • 2016 International Congress

    ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 EASE LID study

    R. Pahwa, C.M. Tanner, R.A. Hauser, P. Nausieda, D.D. Truong, K. Hull, P. Agarwal, R. Johnson, A.E. Ruby, N.L. McClure, M.J. Stempien (Kansas City, KS, USA)

    Objective: To investigate the efficacy and safety of ADS-5102 (amantadine HCl) extended release capsules 340 mg daily at bedtime for the treatment of levodopa-induced dyskinesia…
  • 2016 International Congress

    Validation of an electronic motor diary for patients with Parkinson’s disease

    A. Medina, D. Cerquetti, F. Nanni, M. Rossi, M. Merello (Buenos Aires, Argentina)

    Objective: To determine the reliability and compliance to electronic motor diary in patients with PD. Background: Complexity of motor complications in Parkinson's disease (PD) makes…
  • 2016 International Congress

    Characterization of striatal TH-immunoreactive cells in chronic and acute L-DOPA treatment in a mice model of Parkinson´s disease

    G. Gomez, M. Bordone, S.I. Sanz-Blasco, M.A. Bernardi, J.E. Ferrario, I.R.E. Taravini, M.G. Murer, O.S. Gershanik (Buenos Aires, Argentina)

    Objective: To characterize Tyrosine Hydroxylase immunoreactive cells (TH-ir) in a mouse model of hemiparkinsonism and L-DOPA induced dyskinesia. Background: L-DOPA-induced dyskinesias (LID) are a severe…
  • 2016 International Congress

    The relationship between impulse control disorders and dyskinesia in Parkinson´s disease: The ALTHEA study

    R.J. Vorovenci, L. Weis, R. Biundo, A. Antonini (Venice, Italy)

    Objective: To report (1) the relationship between the occurrence of impulse control disorders (ICDs) and dyskinesias, and (2) the correlations between specific ICDs and the…
  • « Previous Page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • …
  • 40
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley